Holdings
Catalio Capital Management, LP
As of Sep 30, 2026, Catalio Capital Management, LP reported 44 positions worth US$501M. Largest: Avalyn Pharma Inc., Bristol-Myers Squibb Company and BridgeBio Pharma, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Avalyn Pharma Inc. | 1.7M | US$48.4M | +23,021 | Sep 30, 2026 |
| Bristol-Myers Squibb Company | 500K | US$31.2M | +86,755 | Sep 30, 2026 |
| BridgeBio Pharma, Inc. | 425K | US$28M | −29,930 | Sep 30, 2026 |
| Parabilis Medicines, Inc. | 824K | US$26.6M | no change | Sep 30, 2026 |
| Johnson & Johnson | 99,496 | US$26.3M | −39,450 | Sep 30, 2026 |
| Arrowhead Pharmaceuticals, Inc. | 315K | US$20.6M | new | Sep 30, 2026 |
| Syndax Pharmaceuticals, Inc. | 1.02M | US$19.2M | −192K | Sep 30, 2026 |
| Definium Therapeutics, Inc. | 498K | US$19M | −64,708 | Sep 30, 2026 |
| Celcuity Inc. | 231K | US$18.3M | new | Sep 30, 2026 |
| Septerna, Inc. | 454K | US$17.8M | −82,137 | Sep 30, 2026 |